The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting Mayzent (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosis (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…
Alexa
Recommended Posts
- Guest Voice: A 150-mile Bike MS ride comes full circle
- Large study shows how 2 MS treatments stack up in the real world
- Multiple sclerosis has given me plenty of reasons to change my mind
- Probiotics may ease fatigue and pain in MS, review shows
- Scientists uncover immune cell clues behind Epstein-Barr virus link to MS